The next objective of our study was to assess the diagnostic value of NF-L concentration measurements in breast cancer patients and establish cut-off points able to distinguish healthy individuals (control group) from patients with low-grade CIPN G1 (cut-off point 29.5 pg/mL) during treatment monitoring. The gene discussed is NEFL; the disease is breast cancer.